Thioredoxin reductase 1 deficiency enhances selenite toxicity in cancer cells via a thioredoxin-independent mechanism

Biochemical Journal

Volumn 445, Issue 3, 2012, Pages 423-430

  Tobe, Ryuta ^a   Yoo, Min Hyuk ^a   Fradejas, Noelia ^a,b   Carlson, Bradley A ^a   Calvo, Soledad ^b   Gladyshev, Vadim N ^c   Hatfield, Dolph L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer; Glutathione; Selenium cytotoxicity; Selenoprotein; Thioredoxin; Thioredoxin reductase 1

Indexed keywords

GLUTATHIONE; HYDROGEN PEROXIDE; SELENITE; THIOREDOXIN; THIOREDOXIN REDUCTASE 1;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME RELEASE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; ANTICARCINOGENIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; GLUTATHIONE; HYDROGEN PEROXIDE; MICE; NEOPLASMS, EXPERIMENTAL; NIH 3T3 CELLS; OXIDATIVE STRESS; RNA, SMALL INTERFERING; SODIUM SELENITE; THIOREDOXIN REDUCTASE 1; THIOREDOXINS;

MAMMALIA;

EID: 84864346767     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20120618     Document Type: Article

References (54)

1. Fleming, J., Ghose, A. and Harrison, P. R. (2001) Molecular mechanisms of cancer prevention by selenium compounds. Nutr. Cancer 40, 42-49 (Pubitemid 34037513)
2. Hatfield, D. L. and Gladyshev, V. N. (2009) The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology. Mol. Interv. 9, 18-21
3. Jung, H. J. and Seo, Y. R. (2010) Current issues of selenium in cancer chemoprevention. Biofactors 36, 153-158
4. Bellinger, F. P., Raman, A. V., Reeves, M. A. and Berry, M. J. (2009) Regulation and function of selenoproteins in human disease. Biochem. J. 422, 11-22
5. Irons, R., Tsuji, P. A., Carlson, B. A., Ouyang, P., Yoo, M. H., Xu, X. M., Hatfield, D. L., Gladyshev, V. N. and Davis, C. D. (2010) Deficiency in the 15-kDa selenoprotein inhibits tumorigenicity and metastasis of colon cancer cells. Cancer Prev. Res. 3, 630-639
6. Irons, R., Carlson, B. A., Hatfield, D. L. and Davis, C. D. (2006) Both selenoproteins and low molecular weight selenocompounds reduce colon cancer risk in mice with genetically impaired selenoprotein expression. J. Nutr. 136, 1311-1317
7. Kumaraswamy, E., Malykh, A., Korotkov, K. V., Kozyavkin, S., Hu, Y., Kwon, S. Y., Moustafa, M. E., Carlson, B. A., Berry, M. J., Lee, B. J. et al. (2000) Structure-expression relationships of the 15-kDa selenoprotein gene. Possible role of the protein in cancer etiology. J. Biol. Chem. 275, 35540-35547
8. Diwadkar-Navsariwala, V., Prins, G. S., Swanson, S. M., Birch, L. A., Ray, V. H., Hedayat, S., Lantvit, D. L. and Diamond, A. M. (2006) Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model. Proc. Natl. Acad. Sci. U.S.A. 103, 8179-8184 (Pubitemid 43801072)
9. Selenius, M., Rundlof, A. K., Olm, E., Fernandes, A. P. and Bjornstedt, M. (2010) Selenium and the selenoprotein thioredoxin reductase in the prevention, treatment and diagnostics of cancer. Antioxid. Redox Signaling 12, 867-880
10. Hatfield, D. L., Yoo, M. H., Carlson, B. A. and Gladyshev, V. N. (2009) Selenoproteins that function in cancer prevention and promotion. Biochim. Biophys. Acta 1790, 1541-1545
11. Brigelius-Flohe, R. (2008) Selenium compounds and selenoproteins in cancer. Chem. Biodiversity 5, 389-395
12. Rayman, M. P. (2005) Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc. Nutr. Soc. 64, 527-542
13. Lu, J. and Jiang, C. (2005) Selenium and cancer chemoprevention: hypothese integrating the actions of selenoproteins and selenium metabolites in epithelial and non-epithelial target cells. Antioxid. Redox Signaling 7, 1715-1727 (Pubitemid 41781770)
14. Hatfield, D. L., Berry, M. J. and Gladyshev, V. N. (2012) Selenium: Its Molecular Biology and Role in Human Health (3rd ed), pp. 598, Springer, New York
15. Nguyen, P., Awwad, R. T., Smart, D. D., Spitz, D. R. and Gius, D. (2006) Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett. 236, 164-174 (Pubitemid 44262309)
16. Urig, S. and Becker, K. (2006) On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin. Cancer Biol. 16, 452-465 (Pubitemid 44780136)
17. Merrill, G. F., Dowell, P. and Pearson, G. D. (1999) The human p53 negative regulatory domain mediates inhibition of reporter gene transactivation in yeast lacking thioredoxin reductase. Cancer Res. 59, 3175-3179 (Pubitemid 29316019)
18. Moos, P. J., Edes, K., Cassidy, P., Massuda, E. and Fitzpatrick, F. A. (2003) Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J. Biol. Chem. 278, 745-750 (Pubitemid 36790745)
19. Lincoln, D. T., Ali Emadi, E. M., Tonissen, K. F. and Clarke, F. M. (2003) The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res. 23, 2425-2433 (Pubitemid 36897112)
20. Biaglow, J. E. and Miller, R. A. (2005) The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol. Ther. 4, 6-13 (Pubitemid 41350919)
21. Kiermayer, C., Michalke, B., Schmidt, J. and Brielmeier, M. (2007) Effect of selenium on thioredoxin reductase activity in Txnrd1 or Txnrd2 hemizygous mice. Biol. Chem. 388, 1091-1097 (Pubitemid 47584308)
22. Kalantari, P., Narayan, V., Natarajan, S. K., Muralidhar, K., Gandhi, U. H., Vunta, H., Henderson, A. J. and Prabhu, K. S. (2008) Thioredoxin reductase-1 negatively regulates HIV-1 transactivating protein Tat-dependent transcription in human macrophases. J. Biol. Chem. 283, 33183-33190
23. Turanov, A. A., Kehr, S., Marino, S. M., Yoo, M. H., Carlson, B. A., Hatfield, D. L. and Gladyshev, V. N. (2010) Mammalian thioredoxin reductase 1: roles in redox homoeostasis and characterization of cellular targets. Biochem. J. 430, 285-293
24. Gladyshev, V. N., Jeang, K. T. and Stadtman, T. C. (1996) Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc. Natl. Acad. Sci. U.S.A. 93, 6146-6151 (Pubitemid 26190818)
25. Suvorova, E. S., Lucas, O., Weisend, C. M., Rollins, M. F., Merrill, G. F., Capecchi, M. R. and Schmidt, E. E. (2009) Cytoprotective Nrf2 pathway is induced in chronically txnrd 1-deficient hepatocytes. PLoS ONE 4, e6158
26. Kensler, T. W., Wakabayashi, N. and Biswal, S. (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47, 89-116
27. Gandin, V., Fernandes, A. P., Rigobello, M. P., Dani, B., Sorrentino, F., Tisato, F., Bjornstedt, M., Bindoli, A., Sturaro, A., Rella, R. and Marzano, C. (2010) Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem. Pharmacol. 79, 90-101
28. Marzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A. and Rigobello, M. P. (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radical Biol. Med. 42, 872-881 (Pubitemid 46274171)
29. Yan, C., Shieh, B., Reigan, P., Zhang, Z., Colucci, M. A., Chilloux, A., Newsome, J. J., Siegel, D., Chan, D., Moody, C. J. and Ross, D. (2009) Potent activity of indolequinones against human pancreatic cancer: identification of thioredoxin reductase as a potential target. Mol. Pharmacol. 76, 163-172
30. Yoo, M. H., Xu, X. M., Carlson, B. A., Gladyshev, V. N. and Hatfield, D. L. (2006) Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem. 281, 13005-13008 (Pubitemid 43855208)
31. Yoo, M. H., Xu, X. M., Carlson, B. A., Patterson, A. D., Gladyshev, V. N. and Hatfield, D. L. (2007) Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLoS ONE 2, e1112
32. Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70 (Pubitemid 30046295)
33. Husbeck, B., Nonn, L., Peehl, D. M. and Knox, S. J. (2006) Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate 66, 218-225 (Pubitemid 43191243)
34. Menter, D. G., Sabichi, A. L. and Lippman, S. M. (2000) Selenium effects on prostate cell growth. Cancer Epidemiol. Biomarkers Prev. 9, 1171-1182
35. Jonsson-Videsater, K., Bjorkhem-Bergman, L., Hossain, A., Soderberg, A., Eriksson, L. C., Paul, C., Rosen, A. and Bjornstedt, M. (2004) Selenite-induced apoptosis in doxorubicin-resistant cells and effects on the thioredoxin system. Biochem. Pharmacol. 67, 513-522 (Pubitemid 38232891)
36. Bjorkhem-Bergman, L., Jonsson, K., Eriksson, L. C., Olsson, J. M., Lehmann, S., Paul, C. and Bjornstedt., M. (2002) Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase. Biochem. Pharmacol. 63, 1875-1884 (Pubitemid 34603452)
37. Nilsonne, G., Sun, X., Nystrom, C., Rundlof, A. K., Potamitou Fernandes, A., Bjornstedt, M. and Dobra, K. (2006) Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radical Biol. Med. 41, 874-885 (Pubitemid 44262481)
38. Shen, C. L., Song, W. and Pence, B. C. (2001) Interactions of selenium compounds with other antioxidants in DNA damage and apoptosis in human normal keratinocytes. Cancer Epidemiol. Biomarkers. Prev. 10, 385-390 (Pubitemid 32703224)
39. Olm, E., Fernandes, A. P., Hebert, C., Rundlof, A. K., Larsen, E. H., Danielsson, O. and Bjornstedt, M. (2009) Extracellular thiol-assisted selenium uptake dependent on the x(c)- cystine transporter explains the cancer-specific cytotoxicity of selenite. Proc. Natl. Acad. Sci. U.S.A. 106, 11400-11405
40. Bjornstedt, M., Kumar, S. and Holmgren, A. (1992) Selenodiglutathione is a high efficient oxidant of reduced thioredoxin and a substrate for mammalian thioredoxin reductase. J. Biol. Chem. 267, 8030-8034
41. Kumar, S., Bjornstedt, M. and Holomgren, A. (1992) Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large nonstoichiometric oxidation of NADPH in the presence of oxygen. Eur. J. Biochem. 207, 435-439
42. Noda, M., Selinger, Z., Scolnick, E. M. and Bassin, R. H. (1983) Flat revertants isolated from Kirsten sarcoma virus-transformed cells are resistant to the action of specific oncogenes. Proc. Natl. Acad. Sci. U.S.A. 80, 5602-5606 (Pubitemid 14242892)
43. Hissin, P. J. and Hilf, R. (1976) A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal. Biochem. 74, 214-226
44. Halliwell, B. (2007) Oxidative stress and cancer: have we moved forward? Biochem. J. 401, 1-11
45. McEligot, A. J., Yang, S. and Meyskens, Jr, F. L. (2005) Redox regulation by intrinsic species and extrinsic nutrients in normal and cancer cells. Annu. Rev. Nutr. 25, 261-295 (Pubitemid 41209003)
46. Rahman, I., Kode, A. and Biswas, S. K. (2006) Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat. Protoc. 1, 3159-3165
47. Corti, A., Franzini, M., Paolicchi, A. and Pompella, A. (2010) γ-Glutamyltransferase of cancer cells at the cross roads of tumor progression, drug resistance and drug targeting. Anticancer Res. 30, 1169-1181
48. Montero, A. J. and Jassem, J. (2011) Cellular redox pathwas as a therapeutic target in the treatment of cancer. Drugs. 71, 1385-1396
49. Arner, E. S. and Holmgren, A. (2006) The thioredoxin system in cancer. Semin. Cancer Biol. 16, 420-426 (Pubitemid 44780139)
50. Holmgren, A. and Lu, J. (2010) Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem. Biophys. Res. Commun. 396, 120-124
51. Lazard, M., Ha-Duong, N. T., Mounie, S., Perrin, R., Plateau, P. and Blanquet, S. (2011) Selenodiglutathione uptake by the Saccharomyces cerevisiae vacuolar ATP-binding cassette transporter Ycf1p. FEBS J. 278, 4112-4121
52. Hoefig, C. S., Renko, K., Kohrle, J., Birringer, M. and Schomburg, L. (2011) Comparison of different selenocompounds with respect to nutritional value vs. toxicity using liver cells in culture. J. Nutr. Biochem. 10, 945-955
53. Poerschke, R. L. and Moos, P. J. (2011) Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunction. Biochem. Pharmacol. 81, 211-221
54. Mandal, P. K., Schneider, M., Kolle, P., Kuhlencordt, P., Forster, H., Beck, H., Bornkamm, G. W. and Conrad, M. (2010) Loss of thioredoxin reductase 1 renders tumors highly susceptible to pharmacologic glutathione deprivation. Cancer Res. 70, 9505-9514